Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

Rintu Sharma, Pamella Paul, Harjot Singh Vohra, Eshetu Atenafu, John Kuruvilla, Michael Crump, Robert Kridel, Sita Bhella, Vishal Kukreti, Chloe Yang, Abi Vijenthira, Anca Prica, Christine Chen

Blood (2025) 146 (Supplement 1): 5505.

https://doi.org/10.1182/blood-2025-5505

Published: 2025

Journal Articles

Longitudinal assessments of simple frailty tools can help predict outcomes of patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy: A prospective pilot study at Princess Margaret Cancer Centre

Anca Prica, Antonette Pillainayagam, Manjula Maganti, Tiana Coley, Abi Vijenthira, Samantha Mayo, John Kuruvilla, Michael Crump, Sita Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir Alibhai, Christine Chen

Blood (2025) 146 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2025-4530

Published: 2025

Journal Articles

Limited-stage Mantle Cell Lymphoma: Real-world outcomes according to nodal vs. extranodal presentation

Sun-Hye Ko, Michael Crump, John Kuruvilla, David Hodgson, Danielle Rodin, Tomohiro Aoki, Sita Bhella, Robert Kridel, Vishal Kukreti, Nauman Malik, Abi Vijenthira, Chloe Yang, Anca Prica

Blood (2025) 146 (Supplement 1): 2769.

https://doi.org/10.1182/blood-2025-2769

Published: 2025

Journal Articles

The association between neighbourhood walkability and diffuse large B-cell lymphoma: A population-based Study

Elliot Smith, Gillian Booth, Wing Chan, Ning Liu, Mithunan Ravindran, Matthew Cheung, Kelvin Chan, Abi Vijenthira, Peter Gozdyra, Ethan Lin, Lee Mozessohn

Blood (2025) 146 (Supplement 1): 8057.

https://doi.org/10.1182/blood-2025-8057

Published: 2025

Journal Articles

Radiotherapy consolidation post-autologous stem cell transplant in Relapsed/Refractory aggressive non-Hodgkin lymphoma improves progression-free and overall survival in patients with partial but not complete metabolic response pre-transplant

Blood (2025) 146 (Supplement 1): 7188.

https://doi.org/10.1182/blood-2025-7188

Published: 2025

Journal Articles

Outcomes and treatment strategies following CD20/CD3 bispecific antibody failure in non-Hodgkin's lymphoma: A retrospective single-center study

Sun-Hye Ko, Tomohiro Aoki, Robert Kridel, Vishal Kukreti, Anca Prica, Abi Vijenthira, Chloe Yang, Michael Crump, John Kuruvilla

Blood (2025) 146 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2025-4550

Published: 2025

Journal Articles

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I Chen

Blood (2024) 144 (Supplement 1): 7791.

https://doi.org/10.1182/blood-2024-210635

Published: 2024

Journal Articles

Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance

Juan Rangel-Patiño, John Kuruvilla, Anca Prica, Robert Kridel, Sita D. Bhella, Vishal Kukreti, Jan Delabie, Abi Vijenthira, Manjula Maganti, Michael Crump

Blood (2024) 144 (Supplement 1): 2352.

https://doi.org/10.1182/blood-2024-210922

Published: 2024

Journal Articles

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Chathuri Abeyakoon, Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Michael Crump, John Kuruvilla

Blood (2024) 144 (Supplement 1): 1695.

https://doi.org/10.1182/blood-2024-201189

Published: 2024

Journal Articles

Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada

Blood (2024) 144 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2024-209364

Published: 2024

Journal Articles

Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada

Tiana Kordbacheh, Anca Prica, Kelvin KW Chan, Mahmood Aminilari, Zharmaine Ante, Ning Liu, Inna Y Gong, Sita D. Bhella, Michael Crump, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine I Chen, Vishal Kukreti, Chloe Yang, Nauman Malik, David Hodgson, Danielle Rodin

Blood (2024) 144 (Supplement 1): 2272.

https://doi.org/10.1182/blood-2024-201539

Published: 2024

Journal Articles

Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis

Rintu Sharma, John Kuruvilla, Michael Crump, David Hodgson, Yangqing Deng, Abi Vijenthira, Vishal Kukreti, Robert Kridel, Rodger E Tiedemann, Sita Bhella, Chloe Yang, Anca Prica

Blood (2024) 144 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2024-212184

Published: 2024

Journal Articles

Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience

Blood (2024) 144 (Supplement 1): 6548.

https://doi.org/10.1182/blood-2024-205736

Published: 2024

Journal Articles

Outcomes of Patients with Primary Central Nervous System Lymphoma Treated with Matrix Followed By High-Dose Chemotherapy and Autologous Stem Cell Transplant - a Multicentre, Retrospective Study

Adam Suleman, Michael Crump, Graeme Andrew McCrae Fraser, Robert Kridel, Sita D. Bhella, Chloe Yang, Vishal Kukreti, Stephen Ronan Foley, Tom Kouroukis, Amaris Balitsky, John Kuruvilla, Abi Vijenthira, Gwynivere A Davies, Anca Prica

Blood (2024) 144 (Supplement 1): 6281.

https://doi.org/10.1182/blood-2024-198044

Published: 2024

Journal Articles

Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma

Davidson Zhao, Victoria Shelton, Inna Gong, Juan Rangel-Patiño, Ting Liu, Michael Hong, Vanessa Murad, Ur Metser, Anca Prica, Vishal Kukreti, Sita Bhella, Abi Vijenthira, Michael Crump, John Kuruvilla, Bernard Lam, Robert Kridel

Blood (2024) 144 (Supplement 1): 1606.

https://doi.org/10.1182/blood-2024-199677

Published: 2024

Journal Articles

Delays from Progression to Initial Appointment Occur with External Referrals for CAR T-Cell Therapy but Do Not Impact Survival

Sita D. Bhella, Katrina Hueniken, Osamah Jamal S. Jarallah, Melissa Teixeira Maltez, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I Chen

Blood (2024) 144 (Supplement 1): 7581.

https://doi.org/10.1182/blood-2024-211007

Published: 2024

Journal Articles

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Tiana Kordbacheh, Anca Prica, Kelvin KW Chan, Mahmood Aminilari, Zharmaine Ante, Ning Liu, Inna Y Gong, Sita Bhella, Michael Crump, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine I Chen, Vishal Kukreti, Chloe Yang, Nauman Malik, David Hodgson, Danielle Rodin

Blood (2024) 144 (Supplement 1): 5134.

https://doi.org/10.1182/blood-2024-206375

Published: 2024

Journal Articles

COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

Blood (2024) 144 (Supplement 1): 286.

https://doi.org/10.1182/blood-2024-211949

Published: 2024

Journal Articles

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Chathuri Abeyakoon, Vanessa Murad, Ho-Young Yhim, Inna Gong, John Kuruvilla, Michael Crump, Anca Prica, Vishal Kukreti, Sita D. Bhella, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Ur Metser, Robert Kridel, Abi Vijenthira

Blood (2024) 144 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2024-201150

Published: 2024

Journal Articles

Neurocognitive Outcomes over the First 3 Months after Chimeric Antigen Receptor T-Cell (CAR T) Therapy: Preliminary Findings from a Longitudinal Study

Samantha J Mayo, Kim Edelstein, Lori Bernstein, Tiana Coley, Stacey Morrison, Abi Vijenthira, Manjula Maganti, John Kuruvilla, Michael Crump, Sita D. Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir MH Alibhai, Christine Chen, Anca Prica

Blood (2023) 142 (Supplement 1): 3128.

https://doi.org/10.1182/blood-2023-190650

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

Longitudinal assessments of simple frailty tools can help predict outcomes of patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy: A prospective pilot study at Princess Margaret Cancer Centre

Limited-stage Mantle Cell Lymphoma: Real-world outcomes according to nodal vs. extranodal presentation

The association between neighbourhood walkability and diffuse large B-cell lymphoma: A population-based Study

Radiotherapy consolidation post-autologous stem cell transplant in Relapsed/Refractory aggressive non-Hodgkin lymphoma improves progression-free and overall survival in patients with partial but not complete metabolic response pre-transplant

Outcomes and treatment strategies following CD20/CD3 bispecific antibody failure in non-Hodgkin's lymphoma: A retrospective single-center study

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada

Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada

Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis

Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience

Outcomes of Patients with Primary Central Nervous System Lymphoma Treated with Matrix Followed By High-Dose Chemotherapy and Autologous Stem Cell Transplant - a Multicentre, Retrospective Study

Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma

Delays from Progression to Initial Appointment Occur with External Referrals for CAR T-Cell Therapy but Do Not Impact Survival

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Neurocognitive Outcomes over the First 3 Months after Chimeric Antigen Receptor T-Cell (CAR T) Therapy: Preliminary Findings from a Longitudinal Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only